Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world prospective observational study of regorafenib for unresectable hepatocellular carcinoma in central China
ChiCTR1900023703Phase 4Not yet recruiting
- Sponsor
- Renmin Hospital of Wuhan University
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of regorafenib in hepatocellular carcinoma (HCC), sponsored by Renmin Hospital of Wuhan University. Primary endpoint: Progression-free survival. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
regorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1900023703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023703.